Log in
NASDAQ:IRTC

iRhythm Technologies Competitors

$236.27
+11.65 (+5.19 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$218.16
Now: $236.27
$239.27
50-Day Range
$211.45
MA: $234.93
$261.17
52-Week Range
$56.54
Now: $236.27
$274.21
Volume277,343 shs
Average Volume375,125 shs
Market Capitalization$6.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78

Competitors

iRhythm Technologies (NASDAQ:IRTC) Vs. PODD, TFX, NVCR, ABMD, PEN, and HRC

Should you be buying IRTC stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to iRhythm Technologies, including Insulet (PODD), Teleflex (TFX), NovoCure (NVCR), Abiomed (ABMD), Penumbra (PEN), and Hill-Rom (HRC).

iRhythm Technologies (NASDAQ:IRTC) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares iRhythm Technologies and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iRhythm Technologies-28.50%-50.23%-22.26%
Insulet2.20%10.96%1.81%

Valuation & Earnings

This table compares iRhythm Technologies and Insulet's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$214.55 million31.79$-54,570,000.00($2.16)-109.38
Insulet$738.20 million23.75$11.60 million$0.191,399.42

Insulet has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

iRhythm Technologies has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for iRhythm Technologies and Insulet, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iRhythm Technologies03802.73
Insulet110702.33

iRhythm Technologies presently has a consensus target price of $215.80, indicating a potential downside of 8.66%. Insulet has a consensus target price of $235.1875, indicating a potential downside of 11.55%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe iRhythm Technologies is more favorable than Insulet.

Summary

Insulet beats iRhythm Technologies on 7 of the 12 factors compared between the two stocks.

iRhythm Technologies (NASDAQ:IRTC) and Teleflex (NYSE:TFX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares iRhythm Technologies and Teleflex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iRhythm Technologies-28.50%-50.23%-22.26%
Teleflex18.99%17.15%7.91%

Valuation and Earnings

This table compares iRhythm Technologies and Teleflex's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$214.55 million31.79$-54,570,000.00($2.16)-109.38
Teleflex$2.60 billion6.70$461.47 million$11.1533.47

Teleflex has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

iRhythm Technologies has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for iRhythm Technologies and Teleflex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iRhythm Technologies03802.73
Teleflex01913.00

iRhythm Technologies currently has a consensus target price of $215.80, indicating a potential downside of 8.66%. Teleflex has a consensus target price of $384.6364, indicating a potential upside of 3.08%. Given Teleflex's stronger consensus rating and higher probable upside, analysts plainly believe Teleflex is more favorable than iRhythm Technologies.

Institutional & Insider Ownership

91.3% of Teleflex shares are owned by institutional investors. 3.1% of iRhythm Technologies shares are owned by insiders. Comparatively, 2.2% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Teleflex beats iRhythm Technologies on 12 of the 15 factors compared between the two stocks.

iRhythm Technologies (NASDAQ:IRTC) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares iRhythm Technologies and NovoCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iRhythm Technologies-28.50%-50.23%-22.26%
NovoCure4.26%7.40%3.94%

Valuation and Earnings

This table compares iRhythm Technologies and NovoCure's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$214.55 million31.79$-54,570,000.00($2.16)-109.38
NovoCure$351.32 million38.95$-7,230,000.00($0.07)-1,920.14

NovoCure has higher revenue and earnings than iRhythm Technologies. NovoCure is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

iRhythm Technologies has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for iRhythm Technologies and NovoCure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iRhythm Technologies03802.73
NovoCure15402.30

iRhythm Technologies currently has a consensus target price of $215.80, indicating a potential downside of 8.66%. NovoCure has a consensus target price of $102.25, indicating a potential downside of 23.93%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe iRhythm Technologies is more favorable than NovoCure.

Institutional & Insider Ownership

67.6% of NovoCure shares are owned by institutional investors. 3.1% of iRhythm Technologies shares are owned by insiders. Comparatively, 5.1% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NovoCure beats iRhythm Technologies on 10 of the 14 factors compared between the two stocks.

iRhythm Technologies (NASDAQ:IRTC) and Abiomed (NASDAQ:ABMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for iRhythm Technologies and Abiomed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iRhythm Technologies03802.73
Abiomed12302.33

iRhythm Technologies currently has a consensus target price of $215.80, indicating a potential downside of 8.66%. Abiomed has a consensus target price of $223.00, indicating a potential downside of 16.30%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe iRhythm Technologies is more favorable than Abiomed.

Institutional & Insider Ownership

86.0% of Abiomed shares are owned by institutional investors. 3.1% of iRhythm Technologies shares are owned by insiders. Comparatively, 3.4% of Abiomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

iRhythm Technologies has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares iRhythm Technologies and Abiomed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iRhythm Technologies-28.50%-50.23%-22.26%
Abiomed25.89%15.34%13.51%

Valuation and Earnings

This table compares iRhythm Technologies and Abiomed's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$214.55 million31.79$-54,570,000.00($2.16)-109.38
Abiomed$840.88 million14.32$203.01 million$4.7456.21

Abiomed has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Summary

Abiomed beats iRhythm Technologies on 9 of the 14 factors compared between the two stocks.

Penumbra (NYSE:PEN) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Penumbra and iRhythm Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra01602.86
iRhythm Technologies03802.73

Penumbra currently has a consensus price target of $248.8571, indicating a potential downside of 2.30%. iRhythm Technologies has a consensus price target of $215.80, indicating a potential downside of 8.66%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than iRhythm Technologies.

Institutional and Insider Ownership

84.0% of Penumbra shares are owned by institutional investors. 8.9% of Penumbra shares are owned by insiders. Comparatively, 3.1% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Penumbra has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Profitability

This table compares Penumbra and iRhythm Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra2.02%1.25%0.95%
iRhythm Technologies-28.50%-50.23%-22.26%

Earnings & Valuation

This table compares Penumbra and iRhythm Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$547.41 million16.90$48.46 million$0.98259.91
iRhythm Technologies$214.55 million31.79$-54,570,000.00($2.16)-109.38

Penumbra has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Penumbra beats iRhythm Technologies on 11 of the 14 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Earnings & Valuation

This table compares Hill-Rom and iRhythm Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20
iRhythm Technologies$214.55 million31.79$-54,570,000.00($2.16)-109.38

Hill-Rom has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hill-Rom and iRhythm Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.05%25.48%8.66%
iRhythm Technologies-28.50%-50.23%-22.26%

Institutional and Insider Ownership

86.3% of Hill-Rom shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by insiders. Comparatively, 3.1% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Hill-Rom has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Hill-Rom and iRhythm Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
iRhythm Technologies03802.73

Hill-Rom currently has a consensus price target of $116.2857, indicating a potential upside of 19.21%. iRhythm Technologies has a consensus price target of $215.80, indicating a potential downside of 8.66%. Given Hill-Rom's stronger consensus rating and higher probable upside, analysts clearly believe Hill-Rom is more favorable than iRhythm Technologies.

Summary

Hill-Rom beats iRhythm Technologies on 10 of the 14 factors compared between the two stocks.


iRhythm Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
NovoCure logo
NVCR
NovoCure
1.7$134.41+1.5%$13.68 billion$351.32 million707.46
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Penumbra logo
PEN
Penumbra
1.5$254.71+1.7%$9.25 billion$547.41 million878.34
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Haemonetics logo
HAE
Haemonetics
1.4$117.64+1.6%$5.97 billion$988.48 million56.83Increase in Short Interest
Nevro logo
NVRO
Nevro
1.2$170.05+0.7%$5.85 billion$390.26 million-62.52
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.1$92.83+0.6%$5.65 billion$362.30 million-123.77Analyst Downgrade
Heavy News Reporting
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.1$183.14+2.0%$4.93 billion$82.05 million-78.94
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
ICU Medical logo
ICUI
ICU Medical
1.7$185.24+0.2%$3.89 billion$1.27 billion49.01
SWAV
ShockWave Medical
1.2$98.64+0.6%$3.38 billion$42.93 million-46.97Insider Selling
Increase in Short Interest
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.6$54.59+3.5%$3.03 billion$994.85 million-103.00
Glaukos logo
GKOS
Glaukos
0.9$67.02+4.1%$3.01 billion$236.98 million-40.62
Cantel Medical logo
CMD
Cantel Medical
1.5$58.27+3.3%$2.46 billion$1.02 billion142.13
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
SILK
Silk Road Medical
0.9$60.98+2.4%$2.07 billion$63.35 million-52.12
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
AXNX
Axonics Modulation Technologies
1.9$46.30+1.7%$1.84 billion$13.82 million-23.62
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.0$10.38+1.5%$1.76 billion$4.11 million-6.03
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Atrion logo
ATRI
Atrion
0.9$576.60+2.7%$1.07 billion$155.07 million32.48
Cerus logo
CERS
Cerus
1.5$6.26+0.3%$1.05 billion$74.65 million-16.04
Luminex logo
LMNX
Luminex
2.0$21.94+0.2%$1.02 billion$334.64 million56.25Analyst Downgrade
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.8$13.27+1.4%$951.74 million$88.02 million-32.37
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$45.88+0.9%$897.18 million$72.55 million-31.86
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$11.66+3.7%$836.41 million$154.60 million-388.54
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$42.89+0.0%$833.14 million$189.49 million-95.31
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$38.88+2.9%$790.90 million$117.23 million41.81
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
SIBN
SI-BONE
1.4$21.82+1.0%$706.12 million$67.30 million-12.61
VAPO
Vapotherm
1.5$25.78+1.1%$661.54 million$48.10 million-11.41Analyst Upgrade
Increase in Short Interest
Intersect ENT logo
XENT
Intersect ENT
1.2$19.24+3.0%$629.51 million$109.14 million-10.07
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.9$37.17+2.6%$528.37 million$114.51 million-79.09
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
Antares Pharma logo
ATRS
Antares Pharma
2.0$2.86+0.7%$476.68 million$123.86 million47.67
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
RCEL
AVITA Therapeutics
1.3$21.61+5.0%$467.27 million$14.26 million-10.44
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Cytosorbents logo
CTSO
Cytosorbents
1.5$8.79+2.2%$379.52 million$24.95 million-26.64
SeaSpine logo
SPNE
SeaSpine
1.5$13.71+0.9%$378.85 million$159.08 million-7.07Analyst Upgrade
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.3$14.41+0.0%$365.18 millionN/A-6.18
UFP Technologies logo
UFPT
UFP Technologies
1.4$44.53+1.2%$333.75 million$198.38 million18.95
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$86.51+0.8%$314.90 million$46.90 million25.75
IRadimed logo
IRMD
IRadimed
1.5$24.29+2.3%$298.04 million$38.52 million75.91
Co-Diagnostics logo
CODX
Co-Diagnostics
1.8$10.49+5.7%$296.54 million$220,000.0012.95
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.